Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial

Inclusion Criteria: * Infant 6-11 week of age * Infant born after 37-42 week of pregnancy * Infant weighting more than 2.5 kg at birth * Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form * Parents commit themselves to comply with the indication of the investigator and with the schedule of the trial * Mother at least graduate from elementary school * Received Hepatitis B vaccine (Bio Farma) at birth Exclusion Criteria: * Child concomitantly enroll or schedule to be enroll in another trial * Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5 Celsius on Day 0) * Known history of allergy to any component of the vaccine component (e.g.formaldehyde) * History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular injection * Known history of congenital or acquired immunodeficiency (including HIV infection) * Child who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived product or long term corticotherapy (\>2 weeks) * Other vaccination within the 1 month prior to inclusion with the exception of BCG and poliomyelitis * Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objective * Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B infection